CA3073085A1 - Cd38 modulating antibody - Google Patents
Cd38 modulating antibody Download PDFInfo
- Publication number
- CA3073085A1 CA3073085A1 CA3073085A CA3073085A CA3073085A1 CA 3073085 A1 CA3073085 A1 CA 3073085A1 CA 3073085 A CA3073085 A CA 3073085A CA 3073085 A CA3073085 A CA 3073085A CA 3073085 A1 CA3073085 A1 CA 3073085A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- antigen
- binding fragment
- acd38
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546322P | 2017-08-16 | 2017-08-16 | |
| US62/546,322 | 2017-08-16 | ||
| US201762582666P | 2017-11-07 | 2017-11-07 | |
| US201762582653P | 2017-11-07 | 2017-11-07 | |
| US62/582,653 | 2017-11-07 | ||
| US62/582,666 | 2017-11-07 | ||
| PCT/EP2018/065237 WO2018224682A1 (en) | 2017-06-08 | 2018-06-08 | Cd38 modulating antibody |
| EPPCT/EP2018/065237 | 2018-06-08 | ||
| PCT/EP2018/072271 WO2019034752A1 (en) | 2017-08-16 | 2018-08-16 | Cd38 modulating antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3073085A1 true CA3073085A1 (en) | 2019-02-21 |
Family
ID=65361804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3073085A Pending CA3073085A1 (en) | 2017-08-16 | 2018-08-16 | Cd38 modulating antibody |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12304964B2 (enExample) |
| EP (1) | EP3668896A1 (enExample) |
| JP (1) | JP7224338B2 (enExample) |
| KR (1) | KR102770107B1 (enExample) |
| CN (1) | CN111032693B (enExample) |
| AU (1) | AU2018316521B2 (enExample) |
| CA (1) | CA3073085A1 (enExample) |
| SG (1) | SG11202000321PA (enExample) |
| WO (1) | WO2019034752A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| ES3070946T3 (en) | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
| CN116136491A (zh) * | 2021-11-18 | 2023-05-19 | 中山康方生物医药有限公司 | 检测抗cd47抗体的装置和检测方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| US20030148321A1 (en) | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
| AU2011202520C1 (en) | 2002-10-17 | 2016-02-18 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| EP2915820A1 (en) | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| WO2006113747A2 (en) | 2005-04-19 | 2006-10-26 | Prediction Sciences Llc | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
| TW200745162A (en) * | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| AU2016228249A1 (en) | 2006-09-26 | 2016-10-06 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| AU2013209322A1 (en) | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| SG177168A1 (en) | 2006-12-01 | 2012-01-30 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
| CN101605906A (zh) | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2342220B1 (en) | 2008-10-06 | 2021-05-12 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| WO2011035433A1 (en) | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
| MX381912B (es) | 2010-07-16 | 2025-03-13 | Adimab Llc | Colecciones de anticuerpos. |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| BR112015021521A2 (pt) | 2013-03-15 | 2017-10-10 | Genentech Inc | anticorpos anti-crth2 e métodos para seu uso |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| WO2016089862A1 (en) | 2014-12-01 | 2016-06-09 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| CN113527495A (zh) | 2015-04-08 | 2021-10-22 | 索伦托药业有限公司 | 与cd38结合的抗体治疗剂 |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| EP3313441B1 (en) | 2015-06-24 | 2024-02-21 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| KR102770106B1 (ko) | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| US11542338B2 (en) * | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| US12590171B2 (en) | 2019-09-27 | 2026-03-31 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH domain antibodies and use thereof |
-
2018
- 2018-08-16 AU AU2018316521A patent/AU2018316521B2/en active Active
- 2018-08-16 CN CN201880051748.0A patent/CN111032693B/zh active Active
- 2018-08-16 WO PCT/EP2018/072271 patent/WO2019034752A1/en not_active Ceased
- 2018-08-16 JP JP2020508326A patent/JP7224338B2/ja active Active
- 2018-08-16 SG SG11202000321PA patent/SG11202000321PA/en unknown
- 2018-08-16 KR KR1020207003075A patent/KR102770107B1/ko active Active
- 2018-08-16 EP EP18753198.3A patent/EP3668896A1/en active Pending
- 2018-08-16 CA CA3073085A patent/CA3073085A1/en active Pending
-
2022
- 2022-11-30 US US18/060,135 patent/US12304964B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12304964B2 (en) | 2025-05-20 |
| AU2018316521A1 (en) | 2020-02-13 |
| US20230089373A1 (en) | 2023-03-23 |
| KR20200036860A (ko) | 2020-04-07 |
| KR102770107B1 (ko) | 2025-02-20 |
| AU2018316521B2 (en) | 2025-01-30 |
| SG11202000321PA (en) | 2020-02-27 |
| WO2019034752A1 (en) | 2019-02-21 |
| CN111032693A (zh) | 2020-04-17 |
| CN111032693B (zh) | 2023-09-26 |
| JP7224338B2 (ja) | 2023-02-17 |
| EP3668896A1 (en) | 2020-06-24 |
| JP2020531003A (ja) | 2020-11-05 |
| NZ761020A (en) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7596447B2 (ja) | Ｃｄ３８調節抗体 | |
| US20250367286A1 (en) | Cd38 modulating antibody agents | |
| US12162949B2 (en) | CD38 antibody | |
| US12304964B2 (en) | CD38 modulating antibody | |
| US11542338B2 (en) | CD38 modulating antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230512 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240729 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240813 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240813 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240813 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241009 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250102 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250215 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250215 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250805 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250807 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260202 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260210 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260210 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260729 |